In a patient treated for EGFR-mutated cancer, gefitinib concentration was 25.7 ng/mL in cord blood and 1.9 ng/mL in amniotic fluid, which is 20% of the maternal concentration after delivery. The gene discussed is EGFR; the disease is cancer.